Clinical Trials Sponsored by Corpometria Institute

Total 74296 results

National Cancer Institute (NCI)

Active, not recruiting

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Prostate Cancer

United States
Maimónides Biomedical Research Institute of Córdoba
Instituto de Salud Carlos III

Completed

Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients. (CYTOCOR)

Cytomegalovirus Infections | Transplantation Infection

Spain
National Cancer Institute (NCI)

Terminated

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Neoplasms | Biliary Cancer

United States
National Cancer Institute (NCI)

Completed

Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease

Melanoma | Lymphoma | Breast Cancer | Ovarian Cancer | Prostate Cancer

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

A Patient Reminder and Self-Referral Via Online Patient Portals and Text Messaging to Improve Adherence to Breast Cancer Screening (PReVenT)

Breast Carcinoma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Comprehensive Yoga Program (SKY) as Adjunct Therapy for Prostate Cancer

Prostate Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Metastatic Cancer | Solid Tumors

United States
National Cancer Institute (NCI)

Completed

M7824 in Subjects With HPV Associated Malignancies

Cervical Cancer | Anal Cancer | Oropharyngeal Cancer | Human Papilloma Virus | Vaginal or Penile Cancer

United States
National Cancer Institute (NCI)

Completed

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Pancreatic Cancer | Cholangiocarcinoma | Colon Cancer | Liver Metastasis | Metastatic Colon Carcinoma

United States
National Cancer Institute (NCI)

Completed

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Lymphoma, Large B-Cell, Diffuse | Lymphoma, T-Cell, Peripheral | Lymphoma, Large-Cell, Anaplastic | Lymphoma, Extranodal NK-T-Cell | Enteropathy-Associated T-Cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s

Neuroendocrine Tumors | Carcinoma, Neuroendocrine

United States
National Cancer Institute (NCI)

Terminated

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)

Adrenocortical Carcinoma | Adrenocortical Cancer

United States
National Cancer Institute (NCI)

Completed

Pomalidomide for Kaposi Sarcoma in People With or Without HIV

Sarcoma, Kaposi | Kaposi Sarcoma

United States
Douglas Mental Health University Institute
Canadian Institutes of Health Research (CIHR)

Completed

Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis

Psychosis | Social Phobia

Canada
Douglas Mental Health University Institute
Canadian Institutes of Health Research (CIHR)

Completed

Group Cognitive-behavioral Intervention for Social Anxiety in Schizophrenia

Schizophrenia | Social Anxiety

Canada
National Cancer Institute (NCI)

Completed

Cabozantinib for Advanced Urothelial Cancer

Kidney Neoplasms | Urinary Bladder Neoplasms | Urothelial Carcinoma | Urethral Neoplasms

United States
National Cancer Institute (NCI)

Completed

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Triple Negative Breast Cancer | Endometrial Cancer | Hormone Receptor Positive, HER2 Negative Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Pazopanib and ARQ 197 for Advanced Solid Tumors

Solid Tumor

United States
National Cancer Institute (NCI)

Terminated

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Clear-Cell Renal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Bevacizumab for Recurrent Ependymoma

Ependymoma | Anaplastic Ependymoma

United States
National Cancer Institute (NCI)

Completed

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Peripheral T-Cell Lymphoma (PTCL) | T-Cell Prolymphocytic Leukemia | Cutaneous T Cell Lymphoma (CTCL) | T-Cell Lymphoma Relapsed | Adult T-Cell Leukemia (ATL)

United States
National Cancer Institute (NCI)

Terminated

Sunitinib in Sarcomas of the Central Nervous System

Gliosarcoma | Central Nervous System Sarcoma

United States
National Cancer Institute (NCI)

Terminated

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Rhabdomyosarcoma | Rhabdomyosarcoma, Alveolar | Rhabdomyosarcoma, Embryonal

United States
National Cancer Institute (NCI)

Terminated

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Carcinoma, Renal Cell | Gastrointestinal Stromal Tumors | Pheochromocytoma | Paraganglioma | Renal Neoplasms

United States
National Cancer Institute (NCI)

Terminated

A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

Urothelial Cancer

United States
National Cancer Institute (NCI)

Terminated

E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer

Papillomavirus Infections | Oropharyngeal Neoplasms

United States
National Cancer Institute (NCI)

Terminated

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

Melanoma | Sarcoma | Thoracic Sarcomas | Thorasic Cancers | Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Neoplasms | Liver Cancer | Gallbladder Cancer

United States
National Cancer Institute (NCI)

Terminated

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

Mesothelioma

United States
National Cancer Institute (NCI)

Completed

A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women

BRCA1 Gene | BRCA2 Gene

United States
National Cancer Institute (NCI)

Terminated

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

Anal Cancer

United States
National Cancer Institute (NCI)

Completed

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Subcutaneous Panniculitis-Like T-Cell Lymphoma | T-Cell Peripheral Lymphoma | Gamma Delta Hepatosplenic T-Cell Lymphoma | NK T-Cell Lymphoma

United States
National Eye Institute (NEI)

Completed

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

Von Hippel-Lindau Syndrome

United States
Ottawa Heart Institute Research Corporation
Canadian Institutes of Health Research (CIHR)

Completed

Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation (RAFT-AF)

Heart Failure | Atrial Fibrillation

Canada, Taiwan, Sweden, Brazil
National Cancer Institute (NCI)

Completed

NHS-IL12 for Solid Tumors

Epithelial Tumors, Malignant | Epithelial Neoplasms, Malignant | Malignant Mesenchymal Tumor

United States
National Cancer Institute (NCI)

Terminated

Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma

Hodgkin Disease | Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Integrating Use of Self-Affirmation Content Into a Mobile App to Promote Quit Attempts With Text-Based Smoking Cessation Intervention Messaging

Number of Quit Attempts

United States
National Cancer Institute (NCI)

Completed

Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer

Bladder Cancer

United States
National Cancer Institute (NCI)

Terminated

M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Cancer | Cancer of Pancreas

United States
National Cancer Institute (NCI)

Completed

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

Prostatic Neoplasms | Prostatic Cancer

United States
National Cancer Institute (NCI)

Completed

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas

United States
National Cancer Institute (NCI)

Completed

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Melanoma | Breast Cancer | Non-Small Cell Lung Cancer | Meningioma | Hepatocellular Cancer

United States
National Cancer Institute (NCI)

Completed

Risk Factors for Non-HIV-Related Kaposi s Sarcoma

Kaposi's Sarcoma

Italy
National Cancer Institute (NCI)

Terminated

Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)

Monoclonal Gammopathy of Undetermined Significance | Smoldering Myeloma

United States
National Cancer Institute (NCI)

Completed

The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis

AIDS

United States
National Cancer Institute (NCI)

Completed

Effect of Genetic Differences on Levels of Water Disinfection Byproducts in Blood After Showering

Normal Physiology

United States
National Cancer Institute (NCI)

Completed

Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test

Cancers

United States
National Cancer Institute (NCI)

Withdrawn

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Metastatic HPV-16 Positive Squamous Cell Anal Cancer

United States
National Cancer Institute (NCI)

Terminated

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

Renal Cell Carcinoma | Renal Cell Cancer | Hereditary Leiomyomatosis

United States

Clinical Trials Sponsored by Corpometria Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations